Tissue Regenix Group (TRX)

 

TRX Share PerformanceMore

52 week high21.000 03/01/17
52 week low7.800 27/10/17
52 week change -7.125 (-46.34%)
4 week volume32,575,187 24/10/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Tissue Regenix appoints CEO

Tissue Regenix, a regenerative medical devices company, has appointed Steve Couldwell as chief executive officer of the gr...

Appointment of CEO

RNS Number: 3338V Tissue Regenix Group PLC 02 November 2017 Tissue Regenix Group plc Appointment of CEO Steve Couldwell appointed Group CEO Leeds, 02 November 2017 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company announces the appointment of Steve Couldwell, as Chief Executive Off...

Directorate Change

RNS Number: 8786T Tissue Regenix Group PLC 18 October 2017 [This announcement contains inside information.] Tissue Regenix Group plc Directorate Change Leeds, 18 October 2017 - The Board of Tissue Regenix Group plc (AIM:TRX) ("Tissue Regenix" or "The Group") today announces that Antony Odell, Chief Executive Officer (CEO), will be stepping down fro...

Hardman Research: Dual revenue stream growth

RNS Number: 2491T Tissue Regenix Group PLC 11 October 2017 Hardman Research: Dual revenue stream growth Dual revenue stream growth - TRX has a broad portfolio of regenerative medicine products developed from decellularised human and porcine soft tissues for the wound care, orthopaedics, and cardiac markets. Since the launch of DermaPure, focus has...

Unaudited Interim Results

RNS Number: 1381S Tissue Regenix Group PLC 28 September 2017 Tissue Regenix Group plc Unaudited Interim Results for the six months ended 30 June 2017 Leeds, 28 th September 2017 - Tissue Regenix Group (AIM:TRX) "Tissue Regenix" or "The Group", the regenerative medical devices company, today announces its unaudited interim results for the six months en...

Neil Woodford's trades in August 2017

After a busy summer for Neil Woodford, David Brenchley reveals what the star fund manager bought and sold last mon...

Notice of Results

RNS Number: 2015Q Tissue Regenix Group PLC 08 September 2017 Tissue Regenix Group plc Notice of Interim Results and Capital Markets Day Leeds, 8 September 2017 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company, today gives notice that it will announce its interim results for the six months ending...

Notification Of Major Holdings

RNS Number: 8912P Tissue Regenix Group PLC 05 September 2017 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Tissue R...

Fundamental DataMore

EPS-1.27
Dividend yield0 %

Latest discussion posts More

  • Re: CEO steps up

    No response to my email enquiry. Shareholder comms v.poor. But, now we have a new CEO. Been on the board as non exec director since 2013 so he knows how it works. Let?s hope ...
    2-Nov-2017
    theprior
  • Re: CEO steps down

    Worryingly and surprisingly the sp has continued to slip. Something needs to change. Board problems, product problems ? Without some clarification from those on high this ...
    24-Oct-2017
    theprior
  • Re: CEO steps down

    Well its never positive to not have mutually agreed and beneficial outcomes (and statement) as a shareholder you want to think the company has some integrity.More importantly ...
    18-Oct-2017
    Chicken Lips

Users' HoldingsMore

Users who hold Tissue Regenix Group also hold..
LLOYDS GRP.33%
BP23%
SIRIUS MINERALS22%
TAYLOR WIMPEY20%
BARCLAYS17%

Codes & Symbols

ISINGB00B5SGVL29
SymbolsTRX, LSE:TRX, TRX.L, TRX:LN, LON:TRX, XLON:TRX

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account